Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma
Trial Parameters
Brief Summary
To evaluate the efficacy and safety of Xinlikang capsule in the treatment of cancer-related fatigue (CRF) and peripheral blood lymphocytes in patients with diffuse large B-cell lymphoma (DLBCL) who achieved complete remission (CR) after all courses of chemotherapy-containing regimens
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years old; 2. Newly diagnosed diffuse large B lymphoma (DLBCL); 3. Patients had completed the first-line treatment of chemotherapy and immunotherapy and the course of treatment had been completed. 4. Metabolic complete response (CR) was evaluated by PET/CT during or after chemotherapy. 5. Had completed the full course of chemotherapy-containing regimen for more than 30-90 days; 6. BFI fatigue score ≥4; 7. The expected survival time was ≥6 months; 8. No treatment plan for CD20 monoclonal antibody, radiotherapy, chemotherapy, lenalidomide, thymopeptides, targeted drugs, biological agents, immunosuppressive agents, other Chinese medicine decoction or Chinese patent medicine in the next 3 months; 9. No grade 3-4 surgery plan is expected in the next 3 months; 10. They had normal mental consciousness, could understand the content of the questionnaire correctly, and could complete the questionnaire with assistance or independently; 11. Women and men of childbear